TOK-1 inhibitors are a class of chemical compounds that target and inhibit the activity of a specific enzyme or protein known as TOK-1. This enzyme plays a crucial role in various cellular processes, including those involved in signal transduction, protein interactions, and metabolic pathways. The inhibitors of TOK-1 typically act by binding to the active site of the enzyme, thereby preventing its catalytic activity or altering its structural configuration. This inhibition may result in the disruption of normal cellular pathways that are dependent on TOK-1, leading to downstream effects on cellular function and behavior. TOK-1 inhibitors are often designed based on the detailed structure of the enzyme's active or allosteric sites, allowing for precise interaction between the inhibitor and the enzyme. The chemistry behind these inhibitors often involves complex molecular frameworks that maximize binding affinity and selectivity, ensuring that the inhibitor specifically targets TOK-1 without affecting other similar enzymes.
The design and development of TOK-1 inhibitors rely heavily on advanced computational methods, such as molecular modeling, docking studies, and structure-activity relationship (SAR) analysis. These methods help chemists predict how different chemical moieties will interact with the enzyme, enabling the rational design of highly potent inhibitors. Once designed, the chemical synthesis of TOK-1 inhibitors can involve multiple steps, including the introduction of functional groups that enhance solubility, stability, or bioavailability. Characterization of these compounds is essential, often requiring techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and X-ray crystallography to confirm their structure and purity. Additionally, these inhibitors undergo rigorous in vitro testing to assess their potency, selectivity, and potential off-target effects. The complex chemistry behind TOK-1 inhibitors and their ability to specifically modulate enzymatic activity make them a significant focus in biochemical and molecular research.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Inhibits protein kinases, potentially reducing the activity of TOK-1 if it is a kinase. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, which may affect TOK-1 activity if TOK-1 is part of the PI3K/Akt pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Binds to FKBP12 and inhibits mTOR, possibly affecting TOK-1 if it is involved in mTOR signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor that can alter protein degradation pathways, potentially affecting TOK-1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK, which could affect TOK-1 function if it's part of the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAPK, potentially altering TOK-1 activity if it interacts with the p38 pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which may reduce TOK-1 activity if TOK-1 is associated with the JNK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibits PI3K, potentially affecting TOK-1 signaling if it is involved in the PI3K/Akt pathway. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
Inhibits Aurora kinases, possibly affecting TOK-1 if it is related to cell cycle regulation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Src family kinase inhibitor, may alter TOK-1 activity if TOK-1 is part of Src family signaling. | ||||||